Intérêt des hautes doses de cytosine-arabinoside dans le traitement des leucémies aiguës résistantes.
(1987) La Presse Médicale — Vol. 16, n° 4, p. 159-162 (1987)
Files
No attached file found for this publication.
Details
- Authors
- Abstract
- Sixty-one patients with refractory or relapsed or secondary acute leukemia were treated with high-dose cytosine arabinoside (2-3 g/sq m in intravenous infusion every 12 hr to a 12-36 g/sq m total dose). m-Amsa or another antileukemic drug was given with cytosine arabinoside to 20 patients. Complete remission was achieved in 12 of 27 patients with acute myeloid leukemia, 5 of 8 patients with chemotherapy-induced leukemia, 3 of 7 patients with hematologic disorders in blastic crisis and 5 of 17 acute lymphoblastic leukemia patients. A similar response rate (6/16) was obtained when m-Amsa was given with cytosine-arabinoside. The median duration of remission was short (4 months in acute myeloid leukemia). Bone marrow transplantation was performed in 10 patients during the remission time. This regimen has acceptable toxicity; severe neurologic or hepatic disorders occurred in 18% of patients. These data suggest that high-dose cytosine arabinoside is an effective alternative in the treatment of resistant acute leukemia.
- Affiliations
Citations
Witz, F., Olive, D., Lederlin, P., Bordigoni, P., Troussard, X., Grosbois, B., Schaison, G., & Cornu, G. (1987). Intérêt des hautes doses de cytosine-arabinoside dans le traitement des leucémies aiguës résistantes. La Presse Médicale, 16(4), 159-162. https://hdl.handle.net/2078.5/134239 (Original work published 1987)